Clinical Trial Update: Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating RVX000222 in combination with statin therapy for dyslipidemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Dyslipidemia

Drugs mentioned

• RVX000222 (apabetalone)

Snippet

Sponsor: Resverlogix Corp | Conditions: Dyslipidemia, Coronary Artery Disease | Phase 2 | Status: TERMINATED